Pathway Health (TSX-V:PHC) Corp and Canntab Therapeutics Limited are teaming up to deliver Canntab’s oral tablet cannabinoid products within Pathway’s pharmacy network.
The products will consist of a range of both THC and CBD dosages in oral formats, according to a statement from Pathway.
"We are pleased with the opportunity to provide Canntab's oral tablet cannabinoid products to our patients and the patients of our pharmacy partners," said Ken Yoon, CEO of Pathway Health (TSX-V:PHC).
READ: Pathway Health reports fiscal third-quarter financials showing a positive cash position of $4.2M
"We believe CHPs (cannabis health products) will be a key component of any changes made to the Cannabis Act by the federal government, and to this end, we are committed to developing high quality products for our patients and those of our pharmacy partners,” Yoon added.
Pathway Health owns and operates nine community-based clinics across four provinces where its team of health professionals work together to help patients through a variety of evidence-based approaches and products, including medical cannabis. The company also works with several pharmacy companies on the development of CHPs for over-the-counter product distribution through retail pharmacy locations across the country, once changes are made to the Cannabis Act.
READ: Canntab Therapeutics receives medical sales license from Health Canada for its Ontario facility
Canntab Therapeutics is a Canadian biopharmaceutical company that manufactures and distributes a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations.
"We are extremely pleased to have Pathway Health as our first health clinic affiliate partner," said Larry Latowsky, CEO of Canntab Therapeutics. "We are also pleased to support their mission to bring quality delivery formats to their patients and pharmacy partners."
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas